Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8048435 | 0.92 | CYP3A4 (0.50) | GPR119CYP3A4CACNA1BNR1I2KDM4E | |
| SCHEMBL3035026 | 0.88 | GPR119 (0.49) | GPR119CYP3A4CACNA1BNR1I2KDM4E | |
| SCHEMBL2189730 | 0.85 | CYP3A4 (0.46) | GPR119CYP3A4CACNA1BNR1I2KDM4E | |
| SCHEMBL7920460 | 0.85 | CYP3A4 (0.46) | GPR119CYP3A4CACNA1BNR1I2KDM4E | |
| SCHEMBL2196073 | 0.85 | CYP3A4 (0.46) | GPR119CYP3A4CACNA1BNR1I2KDM4E | |
| SCHEMBL3042305 | 0.84 | CYP3A4 (0.49) | CYP3A4CACNA1BNR1I2KDM4ELMNA | |
| SCHEMBL3035563 | 0.82 | CACNA1B (0.64) | CYP3A4CACNA1BNR1I2 | |
| SCHEMBL8050148 | 0.82 | CYP2C9 (0.60) | CYP3A4CACNA1BNR1I2KDM4ELMNA | |
| SCHEMBL3039195 | 0.82 | CACNA1B (0.49) | CYP3A4CACNA1BNR1I2KDM4ELMNA | |
| SCHEMBL7930230 | 0.81 | CNR1 (0.42) | GPR119CYP3A4CACNA1BNR1I2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205083-B1 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | claimed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | claimed |
| EP-2205083-B1 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-8304434-B2 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304434-B2 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304434-B2 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | disclosed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | disclosed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | TRPV1, TRPA1, CACNA1D | GPR119 136/4885CYP3A4 939/4885CACNA1B 23/4885 |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | GPR119 136/4885CYP3A4 939/4885CACNA1B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.